American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Starboard Value’s $1 billion move: will Pfizer see a much-needed revival?

by admin October 7, 2024
October 7, 2024
Starboard Value’s $1 billion move: will Pfizer see a much-needed revival?

In a bid to reshape Pfizer’s future, activist investor Starboard Value has acquired a stake worth approximately $1 billion, according to reports.

The move comes as the pharmaceutical giant faces mounting challenges, including declining demand for its Covid-19 products and increased competition.

Starboard, known for its involvement in strategic shifts at underperforming companies, is expected to push for changes at the New York-based drugmaker.

As of Friday, Pfizer’s market capitalization stood at around $162 billion.

Once a top-performing stock thanks to its role in developing the first Covid-19 vaccine, Pfizer has seen its share price drop by nearly half from its 2021 peak.

Despite this decline, Pfizer’s stock has remained relatively flat this year, in contrast to a 21% rise in the S&P 500.

Former leadership brought in to revamp Pfizer

In its efforts to revamp Pfizer, Starboard has reportedly engaged two former company executives, Ian Read and Frank D’Amelio, who have shown interest in assisting with the investor’s agenda.

Read served as Pfizer’s CEO from 2010 to 2018 and was responsible for appointing the current CEO, Albert Bourla.

D’Amelio held the role of Chief Financial Officer from 2007 to 2021, providing them both with extensive knowledge of the company’s operations and history.

However, the specifics of Starboard’s strategy and discussions with Pfizer remain undisclosed, as per the reports.

Investor pressure on Albert Bourla’s leadership

Pfizer’s CEO, Albert Bourla, has been under increasing pressure from investors as the company grapples with falling sales for its pandemic-related products.

The company misjudged the long-term demand for Covid-19 vaccines and therapeutics once the global health crisis eased, leading to a significant revenue gap.

Despite its groundbreaking success in delivering the Covid-19 vaccine and its antiviral drug, Paxlovid, Pfizer has struggled to sustain the momentum.

The company generated over $100 billion in revenue in 2022, driven by its pandemic products, but demand has since plummeted.

The company’s core portfolio has yet to compensate for the loss, with several key products like the blood thinner Eliquis and arthritis treatment Xeljanz facing looming competition from lower-cost alternatives in the near future.

Adding to Pfizer’s challenges, the company’s initial attempt to develop a weight-loss drug faltered, missing out on the booming market that competitors Eli Lilly and Novo Nordisk have capitalized on.

However, Pfizer is continuing its efforts, advancing a once-daily version of its anti-obesity pill.

Focus shifts to oncology amid Pfizer’s mounting challenges

Pfizer is now betting heavily on its oncology pipeline, particularly after its $43 billion acquisition of biotech company Seagen last year.

Seagen’s cutting-edge cancer therapies, known as antibody-drug conjugates (ADCs), are expected to generate up to $10 billion in annual sales by 2030, according to Pfizer’s projections.

The company has also used its Covid-19 windfall to make other sizable acquisitions, including Arena Pharmaceuticals for $6.7 billion and Biohaven Pharmaceutical for $11.6 billion.

It also spent $5.4 billion on Global Blood Therapeutics, although it recently had to pull all batches of Oxbryta, a sickle-cell treatment it acquired in the deal.

Despite these efforts, some analysts have criticized Pfizer for a perceived lack of focus in its mergers and acquisitions strategy.

Under Ian Read’s leadership, Pfizer was known for narrowing its focus on core areas like vaccines and cancer therapies.

However, Bourla has taken a different approach, significantly ramping up research and development spending while divesting non-core businesses, including its off-patent drug division.

Mixed results and ongoing cost-cutting efforts

Pfizer’s current share price remains below its 2019 level when Bourla first took the helm, signaling investor frustration.

Late last year, the company warned of a potential revenue decline for 2024 and unveiled a $3.5 billion cost-cutting plan to be executed by the end of next year.

In May, the company introduced a new multi-year initiative aimed at further trimming expenses.

In July, Pfizer adjusted its full-year outlook upward, buoyed by newly acquired assets and recent product launches, which helped offset the decline in sales of its Covid-19 vaccine, Comirnaty.

“We are progressing on all cylinders,” Bourla told The Wall Street Journal in an interview in July.

Starboard’s record in pharma and beyond

Starboard, helmed by Jeff Smith, has a long history of driving strategic change across various industries, particularly in the technology sector.

The firm’s previous attempts to shake up the pharmaceutical industry include its unsuccessful effort in 2019 to block Bristol-Myers Squibb’s $74 billion acquisition of rival Celgene.

Starboard has also secured board seats at healthcare-technology company Cerner.

Now, with its sizable investment in Pfizer, Starboard is poised to influence the direction of one of the world’s largest drugmakers, potentially reshaping its future in a rapidly evolving pharmaceutical landscape.

The post Starboard Value’s $1 billion move: will Pfizer see a much-needed revival? appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Is Samsung’s profit recovery stalling amid the AI boom?
next post
BP shifts gears, scales back renewables to regain investor trust: report

Related Posts

Federal Reserve fines Walmart-linked Green Dot Corp $44...

July 23, 2024

Red Lobster files for bankruptcy, but restaurants will...

May 22, 2024

Asian stocks close largely flat: Hang Seng up...

April 29, 2025

Long PPC: Pilgrim’s Pride Rebounds from Composite VPOC...

September 25, 2024

Why analysts are betting on Richemont and Hermes...

April 9, 2025

Toncoin (TON) slumps as Elon Musk denies Telegram-xAI...

May 30, 2025

Why an indicator that has foretold almost every...

July 26, 2024

Elon Musk launches Grok 3: Can xAI’s chatbot...

February 18, 2025

Europe markets open: stocks eye higher start; Mediobanca...

April 28, 2025

Bob Iger says Disney’s mission is to entertain,...

April 6, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • FBI raid on John Bolton’s home in Washington linked to classified documents

      August 25, 2025
    • Argentine senate deals blow to Milei’s austerity agenda with university budget boost

      August 25, 2025
    • Jackson Hole Symposium: what Powell said about economic effects of Trump’s tariffs

      August 25, 2025
    • At Jackson Hole, Fed Chair Powell signals possible cuts while warning of uncertainty

      August 25, 2025
    • Trump threatens to fire Fed Governor Lisa Cook amid mortgage fraud allegations

      August 25, 2025

    Categories

    • Business (3,763)
    • Investing (2,783)
    • Latest News (2,048)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved